Bristol-Myers Squibb Company Ce
CELG-RI
New York Stock Exchange0.11
USD
+0.01
- -
CIK
0000014272
ISIN
US1101221406
CUSIP
110122140
Return %
Stock
S&P500
1Y
290.75
26.53
3Y
-11.98
76.60
5Y
-29.12
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Christopher S. Boerner
- Full Time Employees
- 34,100
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Route 206 & Province Line Road Princeton NJ United States of America 8543
- IPO Date
- Nov 21, 2019
- CIK
- 0000014272
- Website
- bms.com
- Similar Companies
- Business
- Bristol-Myers Squibb Company (NYSE: BMY), a global biopharmaceutical company formed by the 1989 merger of Bristol-Myers (founded 1887) and Squibb (founded 1858) and headquartered in Princeton, New Jersey, discovers, develops, and delivers innovative medicines that help patients prevail over serious diseases in oncology, immunology, cardiovascular, hematology, and neuroscience. The company markets a broad portfolio of branded pharmaceutical products including Eliquis (apixaban; atrial fibrillation anticoagulant, 28% of 2024 revenues), Opdivo (nivolumab; PD-1 immunotherapy for multiple cancers, 19% of 2024 revenues), Revlimid (lenalidomide; multiple myeloma treatment, 12% of 2024 revenues), Orencia (abatacept; rheumatoid arthritis biologic), Pomalyst/Imnovid (pomalidomide; multiple myeloma), Yervoy (ipilimumab; cancer immunotherapy), Reblozyl (luspatercept; anemia in beta thalassemia and myelodysplastic syndromes), Abecma and Breyanzi (CAR T-cell therapies for multiple myeloma and lymphoma), Camzyos (mavacamten; obstructive hypertrophic cardiomyopathy), Sprycel (dasatinib; chronic myeloid leukemia), and Cobenfy (xanomeline/trospium; schizophrenia). It operates worldwide with principal R&D sites in New Jersey, California, Massachusetts, Belgium, Japan, India, and the United Kingdom, generating 71% of 2024 revenues from the United States. Recent strategic moves include the October 2025 acquisition of Orbital Therapeutics for $1.5 billion to bolster its cell therapy portfolio with in vivo CAR T-cell reprogramming technology for autoimmune diseases; the June 2025 global partnership with BioNTech worth up to $11.1 billion to co-develop next-generation bispecific antibody BNT327 for solid tumors; the July 2025 joint venture with Bain Capital to advance immunology therapies; the October 2025 $25 million neuroscience milestone from Evotec collaboration; the August 2025 acquisition of 2seventy bio for $286 million to fully control Abecma CAR-T therapy commercialization; and earlier 2024 acquisitions of Mirati Therapeutics ($4.8 billion plus milestones for oncology), Karuna Therapeutics ($14 billion for KarXT schizophrenia therapy, yielding FDA-approved Cobenfy), and RayzeBio ($4.1 billion for radiopharmaceuticals).